Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adults.

Author: CaubetMagalie, NilssonAnna C, PascalThierry G, PauksensKarlis, PoolmanJan T, Van BellePascale, VandepapelièrePierre G, VerlantVincent, VinkPeter E

Paper Details 
Original Abstract of the Article :
Six vaccine formulations containing AS02V or alum (aluminum phosphate [AlPO4]) adjuvant with pneumococcal proteins, pneumococcal histidine triad D (PhtD), and/or detoxified pneumolysin (dPly), either as a polysaccharide carrier in an 8-valent pneumococcal conjugate vaccine (8PCV) or as free (unconju...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4018883/

データ提供:米国国立医学図書館(NLM)

Pneumococcal Vaccines: A Protective Shield for Elderly Adults

Pneumococcal vaccines protect against infections caused by Streptococcus pneumoniae, a bacterium that can cause pneumonia, meningitis, and other serious illnesses. This phase I study evaluated the safety and immunogenicity, the ability to elicit an immune response, of six different pneumococcal vaccine formulations in elderly adults. The formulations contained various combinations of pneumococcal proteins, including pneumococcal histidine triad D (PhtD) and detoxified pneumolysin (dPly), adjuvanted with either AS02V or alum. The researchers found that all the vaccine formulations were well tolerated, with no serious adverse events reported. The AS02V-adjuvanted formulations tended to elicit higher antibody responses to PhtD and dPly compared to the alum-adjuvanted formulations.

A New Generation of Pneumococcal Vaccines

This study provides valuable insights into the potential of new pneumococcal vaccine formulations for protecting elderly adults, who are at increased risk for pneumococcal infections. The findings suggest that AS02V is a promising adjuvant for enhancing the immunogenicity of pneumococcal vaccines. Further research is needed to confirm these findings in larger clinical trials and to evaluate the long-term efficacy and safety of these new vaccine formulations.

Protecting the Vulnerable

The elderly are particularly vulnerable to pneumococcal infections, which can lead to serious complications, even death. The development of effective pneumococcal vaccines is crucial for protecting this population. This research provides a step forward in the quest to develop safe and effective pneumococcal vaccines that can provide broad protection against a wide range of pneumococcal strains.

Dr. Camel's Conclusion

This research is like a caravan traversing a vast desert, carrying a precious cargo of hope for a healthier future. It reminds us that through scientific innovation, we can create protective shields against the threats that lurk in the vast desert of infectious diseases.

Date :
  1. Date Completed 2014-12-22
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24599529

DOI: Digital Object Identifier

PMC4018883

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.